19 research outputs found
Recommended from our members
A 3D printed drug delivery implant formed from a dynamic supramolecular polyurethane formulation
Using a novel molecular design approach, we have prepared a thermo-responsive supramolecular polyurethane as a matrix material for use in drug eluting implants. The dynamic supramolecular polyurethane (SPU) is able to self-assemble through hydrogen bonding and Ï-Ï stacking interactions, resulting in an addressable polymer network with a relatively low processing temperature. The mechanical properties of the SPU demonstrated the material was self-supporting, stiff, yet flexible thus making it suitable for hot-melt extrusion processing, inclusive of related 3D printing approaches. Cell-based toxicity assays revealed the SPU to be non-toxic and therefore a viable candidate as a biocompatible polymer for implant applications. To this end, the SPU was formulated with paracetamol (16 %w/w) and 4 wt% or 8 wt% poly(ethylene glycol) (PEG) as an excipient and hot melt extruded at 100 °C to afford a 3D printed prototype implant to explore the extended drug release required for an implant and the potential manipulation of the release profile. Furthermore, rheological, infra-red spectroscopy, powder X-ray diffraction and scanning electron microscopy studies revealed the chemical and physical properties and compatibility of the formulation components. Successful release of paracetamol was achieved from in vitro dissolution studies and it was predicted that the drug would be released over a period of up to 8.5 months with hydrophilic PEG being able to influence the release rate. This extended release time is consistent with applications of this novel dynamic polymer as a drug eluting implant matrix
Recommended from our members
Parameters affecting the enhanced permeability and retention effect: the need for patient selection
The enhanced permeability and retention (EPR) effect constitutes the rationale by which nanotechnologies selectively target drugs to tumors. Despite promising pre-clinical and clinical results, these technologies have, in our view, underachieved compared to their potential, possibly due to a suboptimal exploitation of the EPR effect. Here, we have systematically analyzed clinical data to identify key parameters affecting the extent of the EPR effect. An analysis of 17 clinical studies showed that the magnitude of the EPR effect was varied and was influenced by tumor type and size. Pancreatic, colon, breast, and stomach cancers showed the highest levels of accumulation of nanomedicines. Tumor size also had an effect on the accumulation of nanomedicines, with large size tumors having higher accumulation than both medium- and very large- sized tumors. However, medium tumors had the highest percentage of cases (100% of patients) with evidence of the EPR effect. Moreover, tumor perfusion, angiogenesis, inflammation in tumor tissues, and other factors also emerged as additional parameters that might affect the accumulation of nanomedicines into tumors. At the end of the commentary, we propose two strategies for identification of suitable patient sub-populations, with respect to the EPR effect, in order to maximize therapeutic outcome
Recommended from our members
Feasibility of polymer-drug conjugates for non-cancer applications
Polymer-drug conjugates have been intensely studied in the context of improving cancer chemotherapy and yet the only polymer-drug conjugate on the market (MovantikĂ) has a different therapeutic application (relieving opioid-induced constipation). In parallel, a number of studies have recently been published proposing the use of this approach for treating diseases other than cancer. In this commentary, we analyse the many and very diverse applications that have been proposed for polymer-drug conjugates (ranging from inflammation, to cardiovascular diseases) and the rationales underpinning them. We also highlight key design features to be considered when applying polymer-drug conjugates to these new therapeutic areas
Recommended from our members
Conjugation of haloperidol to PEG allows peripheral localisation of haloperidol and eliminates CNS extrapyramidal effects
We have previously reported the synthesis of a poly(ethylene glycol)-haloperidol (PEG-haloperidol) conjugate that retained affinity for its target D2 receptor and was stable in simulated physiological conditions. We hypothesised that this polymer-drug conjugate would localise haloperidol's activity either centrally or peripherally, dependent on the location of administration, due to the polymer preventing penetration through the blood-brain barrier (BBB). Herein, we validate this hypothesis using in vitro and in vivo studies. We first demonstrate, via a [35S]GTPÎłS-binding assay, that drug activity is retained after conjugation to the polymer, supportive of retention of effective therapeutic ability. Specifically, the PEG-haloperidol conjugate (at 10 and 100 nM) was able to significantly inhibit dopamine-induced G-protein activation via D2 receptors, albeit with a loss of potency compared to the free haloperidol (~18-fold at 10 nM). This loss of potency was further probed and rationalised using molecular docking experiments, which indicated that conjugated haloperidol can still bind to the D2 receptors, albeit with a flipped orientation in the binding pocket within the receptor, which may explain the reduced activity. Finally, rat catalepsy studies confirmed the restricted permeation of the conjugate through the BBB in vivo. Rats treated intravenously with free haloperidol became cataleptic, whereas normal behaviour was observed in rats that received the PEG-haloperidol conjugate, suggesting that conjugation can effectively prevent unwanted central effects. Taken together these results demonstrate that conjugating small molecules to polymers is effective at prohibiting penetration of the drug through the BBB and is a valid targeting strategy for drugs to facilitate peripheral (or central) effects without inducing side effects in other compartments
Molecular platforms for targeted drug delivery
The targeted delivery of bioactive molecules to the appropriate site of action, one of the critical focuses of pharmaceutical research, improves therapeutic outcomes and increases safety at the same time; a concept envisaged by Ehrlich over 100 years ago when he described the "magic bullet" model. In the following decades, a considerable amount of research effort combined with enormous investment has carried selective drug targeting into clinical practice via the advent of monoclonal antibodies (mAbs) and antibody-drug conjugates derivatives. Additionally, a deeper understanding of physiopathological conditions of disease has permitted the tailored design of targeted drug delivery platforms that carry drugs, many copies of the same drug, and different drugs in combination to the appropriate site of action least selectively or preferentially. The acquired know-how has provided the field with the design rationale to develop a successful delivery system that will provide new and improved means to treat many intractable diseases and disorders. In this review, we discuss a wide range of molecular platforms for drug delivery, and focus on those with more success in the clinic, given their potential for targeted therapies
Recommended from our members
Biological evaluation of PEG-based conjugates offering localisation of conjugated drugs at the desired compartment
Polymer-drug conjugates (PDCs) are drug delivery systems in which drug molecules are
covalently linked to hydrophilic polymers. These systems have initially been developed to
improve the anticancer efficacy and safety of chemotherapeutic agents based on the enhanced
permeability and retention (EPR) effect. In these applications, the PDCs require the release of
the conjugated drugs within the tumour tissues. However, there are few cases in which the
release of the drug is not the aim. For example, MovantikÂź, the only available PDC on the
market, was developed to prevent the unfavourable penetration of naloxol across the bloodbrain barrier (BBB) while retaining its effect in the intestines. This system was designed as a
non-prodrug employing PEG (as a polymer) and an ether bond as a linker. The current project
focuses on the biological evaluation of utilising the PEGylation strategy to develop non-prodrug
PDCs of haloperidol providing compartmentalisation of haloperidol at the intended site of
action, which could allow potential non-CNS applications of the conjugated haloperidol.
In Chapter 1, a general introduction to the biological barriers, PDCs and their applications
are discussed. The rationale behind this project is also provided.
Chapter 2 identifies the various non-cancer applications of PDCs and key features
influencing the design of such systems for specific diseases are recognised.
Chapter 3 represents a systematic analysis of clinical studies of nanomedicines (including
PDCs) used to treat solid tumours of different origins based on the EPR effect. From all studied
cancers, ovarian, brain, stomach, breast, colon and colorectal, and pancreatic cancers showed
the highest levels(up to >8-fold) of accumulation of nanomedicines compared to other tumours.
Moreover, tumour size was another factor that impacted the accumulation of nanomedicines,
with high levels of accumulation observed in large tumours (~5-fold) compared to medium or
very large tumours. Other parameters such as perfusion levels, the presence of angiogenesis
and inflammation in tumour tissues were identified as factors that might influence the
magnitude of the EPR effect and, as a consequence, the accumulation of nanomedicines within
tumour tissues. The chapter proposes two strategies to select patients who could potentially
benefit from the increased accumulation of nanomedicines based on the EPR effect, which
might enhance the clinical outcomes of using nanomedicines as personalised anticancer agents.
In Chapter 4, the feasibility of utilising the PEGylation strategy to prevent haloperidol
diffusing through the BBB is demonstrated using different in silico, in vitro and in vivo
approaches. The synthesis of a PEG-haloperidol conjugate was carried out (using PEG 6000
Da) by applying a protocol slightly modified based on our previously reported protocol. The in
vitro binding assay indicated that the PEG-haloperidol conjugate had a retained activity through
D2 receptors, however, this was lower than that of the free drug (~18-fold at 10 nM). Molecular
docking (MD) studies indicated that the conjugates exhibited a retained binding affinity for the
D2 receptors, and the binding pattern of the conjugate in the binding pocket explained the loss
of the biological activity of the conjugates compared to the free haloperidol. In vivo studies on
rats revealed that rats treated with PEG-haloperidol were not cataleptic in contrast to the free
haloperidol treated rats, which indicated the prevented crossing of PEG-haloperidol into the
CNS.
Chapter 5 describes potential applications of PEG-haloperidol conjugates in the field of
cancer (acting via s receptors) assessed using in vitro and in silico approaches. PEGs of two
MWs (2000 and 6000 Da) were synthesised. PEG (2000 Da) enhanced the haloperidolâs loading
in the conjugate (~25% w/w) by ~3-fold compared with the loading of haloperidol in PEG
(6000 Da) conjugate. The cytotoxicity of the conjugates was evaluated using breast cancer cell
lines (MCF-7 and MDA-MB 231). The application of the conjugates as potential
antiproliferative agents was limited as their IC50 values were > 100 ”M (compared to ~50 ”M
for the free haloperidol) for both cell lines. The conjugates were also tested for potential antimigratory activity in vitro on vascular endothelial cells (HUVECs). The conjugates
significantly inhibited the VEGF-stimulated migration of HUVECs (> 65% inhibition)
although at a lower level compared to the free haloperidol (91% of inhibition). MD studies were
performed and explained the loss of the biological activity of the conjugates compared to free
haloperidol.
Chapter 6 indicates a preliminary evaluation of potential cardiovascular applications of
PEG-haloperidol by studying its effects on human plateletsâ aggregation induced by CRP-XL
or ADP. The results indicated that free and conjugated haloperidol (at all tested concentrations)
did not significantly abrogate the platelets aggregation stimulated by the CRP-XL (mediated
by GPVI receptors). Moreover, haloperidol and PEG-haloperidol inhibited, however, not
significantly, ADP-induced aggregation of human platelets at concentrations ³12.5 ”M
haloperidol equivalent, probably through P2Y1 receptors. However, further studies by
employing other agonists and/or increasing the incubation time, and using different
methodologies are required to identify the final conclusion.
Chapter 7 represents the feasibility of using PEG-based PDC (designed as a non-prodrug
system) to decrease or avoid the transfer of conjugated drugs through the human placenta. PEG,
as a polymeric carrier, did not significantly affect the apoptosis or proliferation rates within
placental explants when incubated up to 48 h, as indicated via immunohistochemistry staining.
No signs of necrosis were observed when the explants were challenged with PEG as the released
levels of lactate dehydrogenase from the explants did not significantly change. Treatment with
PEG did not alter the normal function of the placental tissues where the secreted levels of hCG
hormone from the explants were not significantly influenced by the polymer. Moreover, the
cellular uptake studies of the PEG-Cy5.5 (dye) and PEG-haloperidol conjugates, used as model
drugs, using fluorescent microscopy and RP-HPLC, respectively, showed complete absence of
PEG-Cy5.5 from the placental tissues and limited uptake of PEG-haloperidol by the tissues
compared to the free Cy5.5 and haloperidol, respectively. This indicated the potential efficiency
of PEGylation strategy to design non-prodrug systems to treat illnesses during pregnancy
without inducing negative effects on the developing fetus.
In Chapter 8, the key findings of this PhD project are summarised, critical evaluation of
work-related aspects and potential future work is suggested. Specifically, taken together, the
data presented in this thesis demonstrated the feasibility of using PEGylated macromolecules
(designed as non-prodrug systems) to reduce or prevent the transfer of conjugated drugs across
biological barriers while retaining their activity. This strategy would form a platform to design
drug delivery systems for applications where specific compartmentalisation of the effects of
drugs is required. Future work will look to investigate this further by exploring PEGylated
systems of therapeutic agents of different classes for their potential clinical applications
Conjugation to PEG as a Strategy to Limit the Uptake of Drugs by the Placenta: Potential Applications for Drug Administration in Pregnancy
Here, we evaluated the feasibility of non-prodrug PEGâdrug conjugates to decrease the accumulation of drugs within the placental tissues. The results showed that PEG was biocompatible with the human placenta with no alteration of the basal rate of proliferation or apoptosis in term placental explants. No significant changes in the released levels of lactate dehydrogenase and the human chorionic gonadotropin were observed after PEG treatment. The cellular uptake studies revealed that conjugating Cy5.5 and haloperidol to PEG significantly reduced (by up to âŒ40-fold) their uptake by the placenta. These findings highlight the viability of novel non-prodrug polymerâdrug conjugates to avoid the accumulation of drugs within the placenta
Recommended from our members
Conjugation to PEG as a strategy to limit the uptake of drugs by the placenta: potential applications for drug administration in pregnancy
Here, we evaluated the feasibility of non-prodrug PEGâdrug conjugates to decrease the accumulation of drugs within the placental tissues. The results showed that PEG was biocompatible with the human placenta with no alteration of the basal rate of proliferation or apoptosis in term placental explants. No significant changes in the released levels of lactate dehydrogenase and the human chorionic gonadotropin were observed after PEG treatment. The cellular uptake studies revealed that conjugating Cy5.5 and haloperidol to PEG significantly reduced (by up to âŒ40-fold) their uptake by the placenta. These findings highlight the viability of novel non-prodrug polymerâdrug conjugates to avoid the accumulation of drugs within the placenta